FDA warned ZOLL Medical after an inspection found quality-system, design-validation, supplier, and reporting failures for defibrillators, ventilators, and electrodes.
What happened
FDA inspected ZOLL’s Chelmsford, MA facility from February 27, 2025 through April 15, 2025 and found the devices adulterated because manufacturing and quality controls did not meet the Quality System regulation. FDA cited failures in corrective and preventive action (CAPA), complaint analysis, MRI compatibility design validation and risk analysis, supplier controls, and a late medical device report for a ventilator shutdown near an MRI.
What FDA found
ZOLL did not follow its CAPA procedure and rejected a CAPA request for a OneStep electrode defect that could cause arcing and burning a patient.
21 CFR 820.100(a)(3)ZOLL’s complaint trend analysis did not escalate repeated MRI ventilator failures or CO2/AccuVent complaints to CAPA.
21 CFR 820.100(a)(1)ZOLL did not adequately validate MRI-compatible ventilator labeling and use with 1.5T scanners.
21 CFR 820.30(g)ZOLL’s health risk assessments and X Series risk analysis were incomplete or did not follow its procedures, including not assessing larger OneStep electrode corrosion.
21 CFR 820.30(g)ZOLL misclassified critical AccuVent Sensor and RescueNet software suppliers and lacked a supplier change-control agreement for RescueNet.
21 CFR 820.50(a)ZOLL reported a June 20, 2024 ventilator shutdown near an MRI to FDA on March 10, 2025, beyond the 30-day requirement.
21 CFR 803.50(a)(2)
What FDA wants
FDA tells ZOLL to provide more information and complete corrective actions on CAPA, complaint review, MRI design validation, risk analysis, supplier controls, and MDR reporting; it also asks for a retrospective complaint review and explanation of component-failure reports that did not trigger CAPA. The provided letter does not state a response deadline.
Who should pay attention
- makers of AEDs and life-support ventilators
- companies relying on critical sensor or software suppliers
- quality teams handling CAPA, complaints, and MDR reporting
This is a summary. Read the original letter on fda.gov.